Abstract: Method and system for adjusting a measured reheat outlet steam temperature (“RPV”) to approximate a reheat outlet steam temperature setpoint (“RSP”) in a boiler. An RPV is compared to an RSP. If the RPV is less than the RSP and a position of a fuel nozzle tilt (“TILTPV”) is below a high limit of the fuel nozzle tilt (“TILTHIGH”), the TILTPV is increased while a flow rate of a secondary flue gas recirculation (“SFGRPV”) is kept constant. If the RPV is less than the RSP and the TILTPV is at the TILTHIGH, the SFGRPV is increased. If the RPV is greater than the RSP and the SFGRPV is greater than a low limit of flow rate of the SFGR (“SFGRLOW”), the SFGRPV is decreased, while the TILTPV is kept constant. If the RPV is greater than the RSP and the SFGRPV is at the SFGRLOW, the TILTPV is decreased.

Abstract: The present invention relates to the technical field of reconstructive plastic surgery and cosmetology, and particularly to a biomimetic chitosan filler for preventing capsular contracture and preparation method thereof. The biomimetic chitosan filler for preventing capsular contracture includes chitosan gel, cross-linked sodium hyaluronate, surfactant, isoosmotic regulator, autologous adipose-derived stem cells, pH adjusting agent and water. The amount of the pH adjusting agent is to adjust a pH value of the chitosan filler to be within a range of 6.5-7.5. The chitosan filler prepared according to the present invention can reduce the inflammation caused by post-operative silica gel exudation, and prevent the occurrence and development of capsular contracture.

Abstract: The present invention relates to the technical field of reconstructive plastic surgery and cosmetology, and particularly to a biomimetic chitosan filler for preventing capsular contracture and preparation method thereof. The biomimetic chitosan filler for preventing capsular contracture includes chitosan gel, cross-linked sodium hyaluronate, surfactant, isoosmotic regulator, autologous adipose-derived stem cells, pH adjusting agent and water. The amount of the pH adjusting agent is to adjust a pH value of the chitosan filler to be within a range of 6.5-7.5. The chitosan filler prepared according to the present invention can reduce the inflammation caused by post-operative silica gel exudation, and prevent the occurrence and development of capsular contracture.

Abstract: An oxy-combustion boiler unit is disclosed which includes a furnace for combusting fuel and for emitting flue gas resulting from combustion. The furnace has first, second and third combustion zones, and an air separation unit for separating oxygen gas from air and providing a first portion of the separated oxygen to a first oxidant flow, a second portion to a second oxidant flow, and a third portion of the separated oxygen gas to the first, second, and third zones of the furnace. A controller can cause the separated oxygen gas to be distributed so that the first and second oxygen flows have a desired oxygen content, and so that the first, second, and third zones of the furnace receive a desired amount of oxygen based on a combustion zone stoichiometry control.

Abstract: The present invention relates to improvements in compositions containing peptides that are ligands of the GHS receptor, or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and methods of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of H-Inp-D-Bal-D-Trp-Phe-Apc-NH2, which is a ligand of the GHS receptor and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms an in situ depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol with an average molecular weight of lower than 1000.

Abstract: The present invention relates to improvements in compositions containing peptides that are ligands of one or more of the melanocortin receptors (MC-R), or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 which is a ligand of the melanocortin receptor subtype 4 (MC4-R), and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms a depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol (PEG) with an average molecular weight of lower than 1000.

Abstract: An oxy-combustion boiler unit is disclosed which includes a furnace for combusting fuel and for emitting flue gas resulting from combustion. The furnace has first, second and third combustion zones, and an air separation unit for separating oxygen gas from air and providing a first portion of the separated oxygen to a first oxidant flow, a second portion to a second oxidant flow, and a third portion of the separated oxygen gas to the first, second, and third zones of the furnace. A controller can cause the separated oxygen gas to be distributed so that the first and second oxygen flows have a desired oxygen content, and so that the first, second, and third zones of the furnace receive a desired amount of oxygen based on a combustion zone stoichiometry control.

Abstract: The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues of IGF-1 having an amino acid substitution at position 59, e.g., (Asn59)hIGF-1(1-70)-OH (SEQ ID NO:1), and other substitution(s) as defined herein.

Abstract: The present invention relates to improvements in compositions containing peptides that are ligands of the GHS receptor, or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and methods of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of H-Inp-D-Bal-D-Trp-Phe-Apc-NH2, which is a ligand of the GHS receptor and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms an in situ depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol with an average molecular weight of lower than 1000.

Abstract: The present invention relates to improvements in compositions containing peptides that are ligands of one or more of the melanocortin receptors (MC-R), or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 which is a ligand of the melanocortin receptor subtype 4 (MC4-R), and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms a depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol (PEG) with an average molecular weight of lower than 1000.

Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.

Abstract: The present invention relates to novel analogues of insulin-like growth factor-1 (IGF-1), pharmaceutical compositions containing said analogues, and the use of said analogues for treatment of IGF-1-receptor mediated conditions, such as short stature, diabetes therapy, neurodegenerative disease treatment, and cartilage repair. More particularly, the present invention relates to novel analogues of IGF-1 having an amino acid substitution at position 59, e.g., (Asn59)hIGF-1(1-70)-OH (SEQ ID NO:1), and other substitution(s) as defined herein.

Abstract: The present invention is directed to improvements in compositions containing a somatostatin-dopamine conjugate which retains both somatostatin and dopamine activity in vivo, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising Dop2-DLys(Dop2)-cyclo[Cys-Tyr-DTrp-Lys-Abu-Cys]-Thr-NH2 (SEQ ID NO: 1), in which the somatostatin-dopamine conjugate precipitates in vivo at physiological pH to form an in situ deposit that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol with an average molecular weight of 400 (PEG400).

Abstract: The invention features targeted cytotoxic compounds and methods relating to their therapeutic use for the treatment of neoplasia and other conditions.

Abstract: The invention is based on the discovery that the levels of one or more methylxanthines in urine samples are significantly decreased in children diagnosed with symptoms of autistic disorder, compared to the levels in normal children, and that levels of xanthines in urine are increased in autistic children. Consequently, the presence in the urine of levels of methylxanthines below a certain range and the level of xanthine above a certain range, are diagnostic of autistic disorder. In another aspect, one or more of these methylxanthines can be used to treat individuals exhibiting symptoms of autistic disorder.

Abstract: The invention is based on the discovery that the levels of one or more methylxanthines in urine samples are significantly decreased in children diagnosed with symptoms of autistic disorder, compared to the levels in normal children, and that levels of xanthines in urine are increased in autistic children. Consequently, the presence in the urine of levels of methylxanthines below a certain range and the level of xanthine above a certain range, are diagnostic of autistic disorder. In another aspect, one or more of these methylxanthines can be used to treat individuals exhibiting symptoms of autistic disorder.